News >

PACIFIC Immunotherapy Data Open Research Opportunities in Stage III NSCLC

Ellie Leick
Published: Wednesday, Aug 07, 2019

Drew Moghanaki, MD, MPH

Drew Moghanaki, MD, MPH

Results from the phase III PACIFIC trial showed an improvement in overall survival with durvalumab (Imfinzi), leading to a new standard of care for select patients with stage III non–small cell lung cancer. Now, Drew Moghanaki, MD, MPH, is asking more questions as the community looks to the future of treatment for this patient population.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication